Clinical Trials
42 results for Prostate Cancer
Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease
- Condition: Prostatic Neoplasms
- Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
- Study ID: NCT01913106
MRI-Guided HDR Brachytherapy for Prostate Cancer
- Condition: Patients With Prostate Cancer
- Intervention: Procedure: MRI Guided Needles to deliver HDR Brachytherapy, Procedure: MRI Guided Needles to deliver HDR Brachytherapy
- Study ID: NCT00913939
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
- Condition: Prostatic Neoplasms
- Study ID: NCT02861573
Fluorine-18 - 2-(3-(1-carboxy-5-[(6-[18F]Fluoro-pyridine-3-carbonyl)-Amino]-Pentyl)-Ureido)-Pentanedioic Acid (18F-DCFPyL) Positron Emission Tomography / Computed Tomography (PET/CT) for Assessment of Recurrent Prostate Cancer
- Condition: Prostatic Neoplasms, Prostate Cancer
- Intervention: Drug: PSMA PET/CT scan
- Study ID: NCT02899312
Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate
- Condition: Locally Recurrent Prostate Cancer
- Intervention: Radiation: Stereotactic Body Radiotherapy
- Study ID: NCT03073278
The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
- Condition: Prostate Cancer, Cardiovascular Disease
- Study ID: NCT03127631
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
- Condition: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Intervention: Drug: Abiraterone, Drug: Bicalutamide, Drug: Degarelix, Drug: Docetaxel, Drug: Flutamide, Drug: Goserelin Acetate, Drug: Histrelin Acetate, Drug: Leuprolide Acetate, Drug: Nilutamide, Procedure: Orchiectomy, Drug: Prednisone, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Procedure: Radical Prostatectomy, Drug: Triptorelin
- Study ID: NCT03678025
Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial
- Condition: Prostate Cancer Metastatic
- Study ID: NCT03655886
High Dose Testosterone in Men With Advanced Prostate Cancer and Homologous Recombination Deficiency
- Condition: Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
- Intervention: Drug: Testosterone Enanthate
- Study ID: NCT03522064
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Condition: Prostate Cancer
- Intervention: Drug: Docetaxel 75 mg/m2, Drug: Docetaxel 60 mg/m2, Drug: Radium-223
- Study ID: NCT03574571
Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Condition: Metastatic Castration-resistant Prostate Cancer
- Study ID: NCT03230734
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Study ID: NCT03874884
Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer
- Condition: Recurrent Prostate Cancer
- Study ID: NCT03067051
A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
- Condition: Metastatic Castration Resistant Prostate Cancer
- Intervention: Drug: Pembrolizumab
- Study ID: NCT04104893
Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
- Condition: Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
- Intervention: Biological: pTVG-HP, Biological: pTVG-AR, Drug: Pembrolizumab, Drug: rhGM-CSF
- Study ID: NCT04090528
PSMA-PET Registry for Recurrent Prostate Cancer Following Radical Prostatectomy
- Condition: Recurrent Prostate Cancer
- Intervention: Diagnostic Test: [18F]-DCFPyL PET/ CT scan (PSMA PET)
- Study ID: NCT03718260
ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Condition: Metastatic Castration-Resistant Prostatic Cancer
- Intervention: Drug: Enzalutamide Oral Capsule [Xtandi], Drug: Abiraterone Oral Tablet [Zytiga], Drug: Carboplatin, Drug: Cabazitaxel 60 mg Solution for Injection, Drug: Docetaxel Injectable Solution, Drug: Radium Chloride Ra-223
- Study ID: NCT03903835
A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)
- Condition: Metastatic Castrate Resistant Prostate Cancer
- Intervention: Drug: Docetaxel, Radiation: Radium 223
- Study ID: NCT03737370
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
- Condition: Metastatic Castration-resistant Prostate Cancer
- Intervention: Drug: REGN5678, Drug: Cemiplimab
- Study ID: NCT03972657
A Study to Evaluate the Safety and Efficacy of IMMU-132 (Sacituzumab Govitecan) in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
- Condition: Prostate Cancer
- Intervention: Drug: IMMU-132
- Study ID: NCT03725761
Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT04506567
68Ga-PSMA-11 PET in Patients With Prostate Cancer
- Condition: Biochemically Recurrent Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Study ID: NCT04777071
Early Detection of Prostate Cancer by Liquid Biopsy
- Condition: Prostate Cancer
- Study ID: NCT04556916
Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment
- Condition: Prostate Cancer, Metastatic Prostate Cancer
- Intervention: Combination Product: Standard of Care, Procedure: Minimally Invasive Ablative Therapy (MIAT), Procedure: Radical Therapy (Prostatectomy or Radiotherapy)
- Study ID: NCT03763253
A Phase IIA Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer
- Condition: Prostate Cancer, Stage IV Prostate Cancer
- Study ID: NCT05189457
A 2-stage, Lead-in and Randomized, Phase 2, Open-label Study of Darolutamide Versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men With Hormone-Naïve Prostate Cancer
- Condition: Biochemically Recurrent Prostate Cancer
- Study ID: NCT05526248
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
- Condition: Biochemically Recurrent Prostate Cancer
- Study ID: NCT05794906
A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM
- Condition: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Study ID: NCT05241860
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
- Condition: Prostatic Neoplasms, Castration-Resistant
- Study ID: NCT04868604
A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT05075577
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT04421222
SatisfACtion: A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With Heavily Pre-treated PSMA Positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy.
- Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Study ID: NCT05983198
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT05803941
A Prospective, Open-label, Multi-center, Single-arm, Phase II Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prosta
- Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Study ID: NCT05670106
An Open-label, Multi-center, Randomized, Phase II Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
- Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Study ID: NCT05658003
A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRP
- Condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Study ID: NCT04597125
A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostat
- Condition: Metastatic Castration-resistant Prostate Cancer
- Study ID: NCT06052306
Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT04946370
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
- Condition: Metastatic Castration-resistant Prostate Cancer, mCRPC
- Study ID: NCT05340374
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer
- Condition: Metastatic Castration-resistant Prostate Cancer, mCRPC, Prostate Cancer
- Study ID: NCT05383079
A Phase I/II Study of Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
- Condition: Cancer Of Prostate, Prostate Neoplasms
- Study ID: NCT04633252
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients With Post-Prostatectomy Biochemical Recurrence
- Condition: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
- Study ID: NCT04423211